Matthews, David J <br/><br/>
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.  [electronic resource] 

 -  Cell cycle (Georgetown, Tex.)  Jan 2007 
 - 104-10 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1551-4005 
<br/><br/><label>Standard No.: </label>10.4161/cc.6.1.3699  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antimetabolites, Antineoplastic--pharmacology<br/>Cells, Cultured<br/>Checkpoint Kinase 1<br/>Checkpoint Kinase 2<br/>Deoxycytidine--analogs & derivatives<br/>Dose-Response Relationship, Drug<br/>Female<br/>Genes, cdc--drug effects<br/>Mice<br/>Mice, Nude<br/>Protein Kinases--metabolism<br/>Protein Serine-Threonine Kinases--metabolism<br/>S Phase--drug effects<br/>Xenograft Model Antitumor Assays--methods<br/>Gemcitabine